Commercial development of organoids culture platform of Living Out

Abstract

In the conventional oncologic approach, patients with the same type of cancer are treated with similar drugs. However, clinical data often show that treatments may work well for some patients and not for others. This is because each patient has a unique profile, which results in different responses to the reference treatments. The use of patient-derived tumor organoids (PDOs) as predictive biomarkers for response to clinical treatment emerges as a potential personalized platform for drug screening for solid tumors. The main goal of Living Out is to develop, with the support of PIPE FASE 2, a drug selection platform with colorectal tumor PDOs, which will be used by the company to offer a personalized treatment selection service. Living Out will therefore operate in a complex market in Brazil that involves the private cancer treatment system. It will be necessary in-depth and detailed studies regarding this market and validations of the hypothesis of our B2B model. In addition, still during PIPE PHASE 2, we will seek important partnerships with large oncology reference centers and health care providers, therefore, specialized legal assistance and support will be needed for decision-making that will influence the future of the business. We believe that with a strong partner in the oncology market, a well-validated business model and a well-defined marketing and marketing strategy, we will have more chances of success when we launch Living Out's service on the market. (AU)